Citations

Clear

14 citation(s) found for "Channick, Richard".

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment
Osterhout, Robin , Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Roscigno, Robert F., Mottola, David, Sitapara, Ravi, Aranda, R., Zisman, Lawrence S. , Bruey, Jean‐Marie, Zamanian, R.T., Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Sitapara, Ravikumar

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804783 Get It

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, R., Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard, Frantz, R, McLaughlin, V.V., Vachiéry, J, Zamanian, R.T., Cravets, Matt , Roscigno, Robert F., Mottola, David, Parsley, Ed, Aranda, R., Zisman, Lawrence S. , Ghofrani, Hossein Ardeschir , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B, Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804612 Get It

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)
Held, Matthias , Benza, R.L., Channick, Richard, Chin, K. , Frantz, R, Howard, L, McLaughlin, Vallerie V. , Zamanian, R.T., Bruey, Jean‐Marie, Cravets, Matt , Mottola, David, Zisman, Lawrence S. , Parsley, Ed, Roscigno, Robert F., Aranda, R., Vachiéry, J, Sitbon, Olivier , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , McLaughlin, Vallerie V.

Mayo Clinic

Pneumologie | March 18, 2025 | Volume: 79 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1804609 Get It

Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates With Hemodynamics and Is Consistent With REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Lachant, Daniel , Osterhout, Robin , Chakinala, Murali M. , Franco, Verónica , McConnell, J.W. , Rahaghi, Franck , Sood, Namita , Spikes, Leslie , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Zamanian, R.T., Roscigno, R.F., Mottola, David, Parsley, E., Cravets, Matt , Bruey, Jean Marie, Zisman, Lawrence S. , White, R.J., Osterhout, Robin E. , Sahay, Sandeep , Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , White, R. James

Mayo Clinic

D109. NOW WE GOT BAD BLOOD: RSF/PC JOINT SESSION ON PULMONARY VASCULAR DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7475-A7475

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7475 Get It

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation, and Fibrosis Improve With Treatment
Osterhout, Robin , Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Roscigno, R.F., Mottola, David, Sitapara, Ravikumar , Aranda, R., Zisman, Lawrence S. , Bruey, Jean Marie, Zamanian, Roham T. , Ghofrani, Hossein Ardeschir , Osterhout, Robin E. , Benza, Raymond L. , Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier

Mayo Clinic

D105. BALBOA PARK EXPLORERS: TRANSLATIONAL SCIENCE AND EPIDEMIOLOGY IN PH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7383-A7383

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7383 Get It

Interim Results From the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)
Zolty, Ronald , Kingrey, J.F. , Penn, Benjamin G., Sobol, Irina , Sood, Namita , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Sitbon, Olivier , Sahay, Sandeep , Subías, Pilar Escribano , Penn, B., Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Ghofrani, Hossein Ardeschir

Mayo Clinic

A14. BUILDING LEGO(LAND): LESSONS LEARNED FROM LARGE SCALE CLINICAL TRIALS IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1011-A1011

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1011 Get It

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
McLaughlin, V.V., Zolty, Ronald , Channick, Richard N. , Chin, K. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Elman, Erin, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Frantz, Robert P. , Sahay, Sandeep , Subías, Pilar Escribano , Benza, Raymond L. , Channick, Richard N. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Ghofrani, Hossein Ardeschir

Mayo Clinic

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6726 Get It

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
McLaughlin, Vallerie V. , Channick, Richard N. , Kim, Nick H. , Frantz, Robert P. , McConnell, John W., Melendres‐Groves, Lana , Miller, Chad E., Rodriguez‐Lopez, Josanna , Brand, Monika, Leroy, Sandrine, Wetherill, Graham, Chin, Kelly , Chin, Kelly M , Frantz, Robert P , McLaughlin, Vallerie V. , Channick, Richard N. , Ravichandran, Ashwin Kumar , Leroy, Sandrine

Mayo Clinic

Pulmonary Circulation | October 21, 2022 | Volume: 12 | Issue: 4 | Pages: No page available

10.1002/pul2.12150 | PMID 36381290 Get It

AbstractMacitentan is an oral endothelin receptor antagonist for the management of pulmonary arterial hypertension (PAH). The OPsumit® USers Registry (OPUS) and the OPsumit® Historical USers cohort (OrPHeUS) medical chart review provide real‐world data for patients newly initiating macitentan. This study aims to describe the characteristics, safety profile, and clinical outcomes of PAH patients newly treated with macitentan in the combined OPUS/OrPHeUS data set. OPUS was a prospective, multicenter, long‐term, observational drug registry from April 2014 to June 2020. OrPHeUS was a retrospective, US, multicenter chart review: observation period October 2013 to March 2017. All analyses were descriptive. At registry closure in June 2020, the combined population consisted of 5654 patients, of whom 81.9% were diagnosed with PAH. For these 4626 patients, median duration of macitentan exposure observed was 14.5 (Q1 = 5.2, Q3 = 29.0) months; idiopathic PAH (54.8%) was the most common form of PAH; macitentan was initiated as monotherapy (37.9%), or as part of double (48.0%) or triple therapy (14.1%); discontinuation due to nonhepatic/hepatic adverse events occurred in 17.1%/0.3% of patients; 9.9% of patients experienced ≥1 hepatic adverse events; Kaplan–Meier estimates showed that at 1 year 59.9% (95% confidence interval: 58.3, 61.5) of patients were free from hospitalization and survival was 90.4% (89.3, 91.3). This analysis of real‐world data from the combined OPUS and OrPHeUS populations demonstrated that macitentan is well tolerated in a large, diverse population of PAH patients, with overall and hepatic safety profiles consistent with previous macitentan clinical trials.
TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
Benza, Raymond L. , Channick, Richard N. , Chin, Kelly , McLaughlin, Vallerie V. , Zamanian, Roham T. , Cravets, Matt , Bruey, Jean‐Marie, Roscigno, R.F., Mottola, David, Elman, Erin, Zisman, Lawrence S. , Ghofrani, Hossein‐Ardeschir, Chin, Kelly M , Benza, Raymond L. , Frantz, Robert P. , Channick, Richard N. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , Hemnes, Anna R. , Ghofrani, Hossein‐Ardeschir

Mayo Clinic

Pulmonary Circulation | October 22, 2021 | Volume: 11 | Issue: 4 | Pages: 1-7

10.1177/20458940211057071 | PMID 34790348 Get It

Aberrant kinase signaling that involves platelet‐derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c‐KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension. Targeting these specific pathways may potentially reverse the pathological inflammation, cellular proliferation, and fibrosis associated with pulmonary arterial hypertension progression. Seralutinib (formerly known as GB002) is a novel, potent, clinical stage inhibitor of PDGFRα/β, CSF1R, and c‐KIT delivered via inhalation that is being developed for patients with pulmonary arterial hypertension. Here, we report on an ongoing Phase 2 randomized, double‐blind, placebo‐controlled trial (NCT04456998) evaluating the efficacy and safety of seralutinib in subjects with World Health Organization Group 1 Pulmonary Hypertension who are classified as Functional Class II or III. A total of 80 subjects will be enrolled and randomized to receive either study drug or placebo for 24 weeks followed by an optional 72‐week open‐label extension study. The primary endpoint is the change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization. The secondary endpoint is the change in distance from baseline to Week 24 achieved in the 6‐min walk test. A computerized tomography sub‐study will examine the effect of seralutinib on pulmonary vascular remodelling. A separate heart rate monitoring sub‐study will examine the effect of seralutinib on cardiac effort during the 6‐min walk test.